Jim Cramer Calls Merck His Top Defensive Stock Pick
Cramer singles out Merck as his go-to defense play. Here's the tradeable case for MRK in a volatile market.
Jim Cramer has a favorites list when markets get choppy, and right now Merck sits at the top of it. The CNBC host dubbed MRK his "fantasy defense stock," a label that carries weight when Wall Street is cycling out of growth names and hunting for shelter.
Defensive stocks are the backbone of a recession-resistant portfolio. Pharma fits that mold because people don't stop buying medicine when the economy slows. Merck, with its deep drug pipeline and blockbuster franchise, checks the boxes Cramer looks for when he wants to play it safe without sitting on the sidelines entirely.
Read more Samsara Stock Tops $2B Revenue But Hardware Costs Bite →
For retail traders, the Cramer endorsement alone can move a ticker short-term, but the longer thesis here is about durability. MRK isn't a momentum trade — it's the kind of position you build when you're worried the broader market hasn't finished its slide and you still want equity exposure working for you.
The broader context matters too. Rate uncertainty, geopolitical noise, and mixed earnings signals have pushed a lot of traders toward sectors that can absorb punishment. Healthcare, and Merck specifically, keeps appearing on that short list for a reason: predictable revenue streams are hard to find right now.
If you're building a watchlist for the next leg down, Cramer's framing of Merck as a fantasy defense name is worth taking seriously. Continue reading at Yahoo Finance.
